Navigation Links
Bird flu mutation study offers vaccine clue
Date:4/8/2013

Scientists have described small genetic changes that enable the H5N1 bird flu virus to replicate more easily in the noses of mammals.

So far there have only been isolated cases of bird flu in humans, and no widespread transmission as the H5N1 virus can't replicate efficiently in the nose. The new study, using weakened viruses in the lab, supports the conclusions of controversial research published in 2012 which demonstrated that just a few genetic mutations could enable bird flu to spread between ferrets, which are used to model flu infection in humans.

Researchers say the new findings could help to develop more effective vaccines against new strains of bird flu that can spread between humans.

"Knowing why bird flu struggles to replicate in the nose and understanding the genetic mutations that would enable it to happen are vital for monitoring viruses circulating in birds and preparing for an outbreak in humans," said Professor Wendy Barclay, from the Department of Medicine at Imperial College London, who led the study.

"The studies published last year pointed to a mechanism that restricts replication of H5N1 viruses in the nose. We've engineered a different mutation with the same effect into one of the virus proteins and achieved a similar outcome. This suggests that there is a common mechanism by which bird flu could evolve to spread between humans, but that a number of different specific mutations might mediate that."

Bird flu only rarely infects humans because the human nose has different receptors to those of birds and is also more acidic. The Imperial team studied mutations in the gene for haemagglutinin, a protein on the surface of the virus that enables it to get into host cells. They carried out their experiments in a laboratory strain of flu with the same proteins on its surface as bird flu, but engineered so that it cannot cause serious illness.

The research found that mutations in the H5 haema
'/>"/>

Contact: Sam Wong
sam.wong@imperial.ac.uk
44-207-594-2198
Imperial College London
Source:Eurekalert

Page: 1 2

Related biology news :

1. One gene, many mutations
2. Found a genetic mutation causing mental retardation very similar to Angelman syndrome in Amish
3. Sleator lab identifies single point mutation in Listeria monocytogenes
4. Why a hereditary anemia is caused by genetic mutation in mechanically sensitive ion channel
5. Mutation altering stability of surface molecule in acid enables H5N1 infection of mammals
6. Research discovers gene mutation causing rare eye disease
7. Animal model of human evolution indicates thick hair mutation emerged 30,000 years ago
8. Consumers have few negative reactions to the results of genetic testing for cancer mutations
9. Mitochondrial mutations: When the cells 2 genomes collide
10. Researchers discover mutations linked to relapse of childhood leukemia
11. Gene mutation immortalizes malignant melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , July 27, 2015   Zynx Health ... experience-based clinical improvement solutions, today announced that its ... now available on Android smartphones and tablets. With ... post-care organizations can use ZynxCarebook to securely exchange ... condition, streamline care transitions to other care settings, ...
(Date:7/21/2015)... YORK , July 21, 2015 ... systems, as seen in the recent U.S. Office ... a solution to the infosec conundrum, but developers ... is stored. To address this dilemma, Biometrics-as-a-Service provider ... its Biometric Tokenization SDK for third party integration. ...
(Date:7/9/2015)... , July 07, 2015 ... announced the addition of the "Biometrics for ... Forecasts 2015-2020" report to their offering. ... major contributor to this growth and the forecast ... billion in revenue for companies involved in delivering ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... For the first time in nearly a century drinkers will ... heritage barley from the Victorian period. Old varieties ... the John Innes Centre revived Chevallier from the institute,s Genetic ... records indicate that the variety produced premium quality malt and ...
... analysis, carbon dioxide removal could be used under certain ... but it would not replace the bulk of actual ... allows to separate emissions control from the time and ... important for climate protection," says lead-author Elmar Kriegler. "You ...
... "Many of the great whales which once populated the oceans ... commercial hunting. The committee also worried about how tuna fishing ... And they considered reports about seal hunting and the decline ... October of that year, Congress passed the Marine Mammal Protection ...
Cached Biology News:Cheers to better beer and disease resistance 2CO2 removal can lower costs of climate protection 2CO2 removal can lower costs of climate protection 3Sea mammals find US safe harbor 2Sea mammals find US safe harbor 3Sea mammals find US safe harbor 4
(Date:7/30/2015)... , ... July 30, 2015 , ... ... of a field clinical study of its canine osteoarthritis stem cell product, currently ... Therapeutics (Kansas City, KS) and will be marketed in the US by Aratana. ...
(Date:7/30/2015)... Senomyx , Inc. (NASDAQ: SNMX ), a leading ... and commercialize novel flavor ingredients for the food, beverage, ... the second quarter 2015. "Moving into ... to achieve our commercial and financial goals," stated John ... "Since our last quarterly earnings report, our two partners ...
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
(Date:7/30/2015)... July 30, 2015  Discovery Laboratories, Inc. (Nasdaq: ... received the second $1.0M tranche under a previously ... grant valued at up to $3.0 million to ... surfactant as a potential medical countermeasure to mitigate ... was awarded an initial $1.0 million under this ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... Calif., Aug. 19 ReceptorBio,Inc. announced today that ... Inc. (Palo Alto, CA) (Nasdaq: TELK ) ... unique, oral small molecule insulin,receptor activators. These compounds ... drug discovery technology. The,agreement provides for payments related ...
... software,solutions provider for cheminformatics today announced the launch ... JChem. As well as,other improvements, the release sees ... 2 format useful for integrating with Microsoft Office,applications., ... of application programming,interfaces (API,s) and graphic user interfaces ...
... 19 Today Bavarian,Nordic published the company,s interim report ... available on the company,s website. Below is an,extract of ... as events,after the balance sheet date., In the ... DKK 23,million and recorded a loss before tax of ...
Cached Biology Technology:ReceptorBio Announces Diabetes License Agreement With Telik 2ReceptorBio Announces Diabetes License Agreement With Telik 3ChemAxon Launches Marvin and JChem Version 5.1; Name to Structure Generation, OLE 2 and JavaScript Integration 2Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008 2Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008 3Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008 4Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008 5Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008 6Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008 7Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008 8Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008 9Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008 10
Rabbit polyclonal to KIAA1276 ( Abpromise for all tested applications). entrezGeneID: 27146 SwissProtID: Q9ULE4...
Mouse monoclonal [LH8] to Cytokeratin 5 + 14 ( Abpromise for all tested applications). entrezGeneID: 3852 SwissProtID: P02533...
Rabbit polyclonal to IL23 P19 ( Abpromise for all tested applications). Antigen: Synthetic 16 amino acid peptide from near the amino terminus of human IL23 P19 Entrez Gene ID: 51561 Swiss...
Complement C1q subcomponent subunit C precursor. [Source:Uniprot/SWISSPROT;Acc:P02747] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: